Ef-32: Pivotal, Randomized, Open-Label Study Of Optune® (Tumor Treating Fields, 200Khz) Concomitant With Radiation Therapy And Temozolomide For The Treatment Of Newly Diagnosed Glioblastoma
Posted Date: May 20, 2021
- Investigator: Kyle Wang
- Specialties: Cancer, Oncology
- Type of Study: Device & Drug
The purpose of this study is to test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued following radiation therapy. Effectiveness will be determined by measuring Overall Survival Rate.
Criteria:
Must Have Confirmed Diagnosis Of Gbm, Planned Treatment With Rt/Tmz Followed By Ttfields And Maintenance Tmz, Karnofsky Performance Status = 70, Life Expectancy = Least 3 Months, No Progressive Disease, No Significant Co-Morbidities At Baseline Which Woul
Keywords:
Glioblastoma, Gbm, Radiation
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com